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ABSTRACT 
 
Objectives: To evaluate the ability of estimation of serum expression levels of micro RNA (miR-141 
and miR-215 to differentiate between liver cirrhosis, chronic hepatitis C (CHC) and hepatocellular 
carcinoma (HCC) patients. 
Original Research Article 
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Patients and Methods: The study included 25 liver cirrhosis patients, 25 CHC patients, 25 HCC 
patients and 15 volunteers (Control group). All patients underwent clinical examination, preliminary 
investigations and radiological workup. Fasting blood samples were withdrawn from all patients and 
controls for estimation of serum levels of α-fetoprotein (AFP), quantitative PCR estimation of HCV 
RNA titers and real-time PCR quantitation of serum expression levels of miR-215 and miR-215 -141. 
Results: Serum AFP levels were significantly higher in HCC patients than cirrhosis and CHC 
patients. Estimated serum expression levels of miR-215 were significantly higher in CHC and HCC 
patients compared to both controls and cirrhosis, while serum expression levels of miR-141 were 
significantly lower in HCC patients compared to controls and cirrhosis patients and in CHC patients 
than controls. Estimated HCV viral load in CHC patients showed positive significant correlation with 
serum expression level of miR-215, while showed non-significant correlation with miR-141. 
Estimated serum levels of miR-215 and miR-141 could differentiate hepatic patients and controls 
with AUC= 0.872 and 0.250, respectively. Whereas, estimated serum levels of miR-215 could 
differentiate between cirrhosis and CHC patients with AUC= 0.899. Estimated serum levels of miR-
215 and miR-141 also could be used to identify HCC patients out of hepatic disease patients with 
AUC of 0.818 and 0.351, respectively. 
Conclusion: Serum expression levels of miR-215 and miR-141 could be used to identify hepatic 
disease patients with high positive predictive value (PPV) especially miR-215. miR-215 can 
differentiate between cirrhosis and CHC patients and correlated with HCV load. Serum levels of 
both miRs could assure diagnosis of HCC with high PPV. 
 
 
Keywords: Hepatic diseases; miR-215; miR-141; HCC patients detection. 
 
1. INTRODUCTION 
 
Chronic hepatitis C virus (HCV) infection is a 
major health problem worldwide [1] and is a 
major risk factor for the development of 
hepatocellular carcinoma (HCC) [2]. However, 
the best means for evaluating liver impairment is 
still a major clinical challenge [3] and the 
diagnosis of cirrhosis portends an increased risk 
of morbidity and mortality [4].  
 
Liver biopsy despite of being the gold standard 
for diagnosis of cirrhosis and staging of fibrosis 
(4) and to assess histological activity of HCV [5], 
it is an invasive procedure and has been 
associated with sampling error mostly due to 
suboptimal biopsy size [3]. Noninvasive testing 
has been shown to be equally predictive in ruling 
out or ruling in advanced fibrosis [6] and are 
becoming standard of care, which significantly 
reduces the need for liver biopsy [7]. 
 
Hepatocellular carcinoma is one of the most 
prevalent malignancies in the world
 
[8]. HCC is 
one of the leading causes of cancer deaths and 
its current modes of treatment still palliative [9]. 
Diagnostic ability of estimated serum levels of 
liver enzymes is limited, but could be used to 
evaluate the response to treatment [10]. 
 
Micro RNAs (MiRs) are a class of endogenous 
small non-coding single-strand RNA molecules 
[11] that regulate gene expression at the post-
transcriptional level [12]. In humans, more than 
2000 mature MiRs have been identified [13].and 
affect the pathophysiology of internal diseases 
and can also reflect their presence [14]. 
 
Circulating MiRs are MiRs present in 
extracellular space including all body fluids and 
are released into the circulation either after the 
cell necrosis or by active transport [15]. 
Circulating miRs are stable with constant levels 
among the individuals of one species, methods 
determining their levels are reproducible and 
their levels differ between healthy and diseased 
individuals [14]. Changes of circulating miRs 
level occur in early oncogenesis, so could be a 
potential biomarkers for early detection of cancer 
[16]. 
 
The aim of the study was to evaluate the ability 
of estimation of the serum expression levels of 
miR-141 and miR-215 to differentiate between 
liver diseases especially cirrhosis and CHC 
which are the precursors of HCC
 
[17,18,19]. 
 
2. PATIENTS AND METHODS 
 
The current study was conducted at Departments 
of Tropical Medicine and Microriology, at Alansar 
and Saudi German Hospital, Saudia Arabia since 
June 2015 till Dec 2016. The study protocol was 
approved by Local Ethical Committee. All 
enrolled patients signed written fully informed 
consent for study participation and undergoing 
assigned investigations.  
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Table 1. Criteria and score points for calculation of Child-Pugh score
 
[20] 
 
Criteria                    Score (points) 
1 2 3 
Serum total bilirubin  <2 mg/dl 2-3 mg/dl >3 mg/dl 
Serum albumin >3.5 g/dl 2.8-3.5 g/dl <2.8 g/dl 
International normalized ratio (INR) <1.7 1.71-2.20 >2.2 
Ascites No Present  Tense  
Encephalopathy No Grade I or II Grade III or IV 
 
Table 2. Primers for amplification of miR-215 and miR-141 expression 
 
Primer  Sequence  REF 
MiR-215  5’-ATG ACC TAT GAA TTG ACA GAC AA-3’ (5’-3’sequence forward)  
5’-GCT GTC AAC GAT ACG CTA CGT-3’5’-3’ (5’-3’sequence reverse)  
25 
MiR-141 5’-CTG CCT TTA CAG CAA GAT-3’ (5’-3’sequence forward)  
5’-TTT ATT TCA TGC TCC CAA GGC GGG-3’ (5’-3’sequence reverse)  
26 
U6 5’- CGC TTC GGC AGC ACA TAT AC-3’ (5’-3’ sequence forward) 
5’-TTC ACG AAT TTG CGT GTC AT-3’ (5’-3’ sequence reverse). 
25 
 
2.1 Preliminary Evaluation 
 
Demographic data included age, gender and 
body mass index (BMI) data.Routine liver 
function tests including estimation of serum 
alanine transaminase (ALT), aspartate 
transaminase (AST), total bilirubin (TB), albumin 
and calculation of international normalized ratio 
(INR). Screening for hepatitis (HBsAg and HCV 
antibodies) was done using commercially 
available kits (Bio-RADFrance) with PEB III 
(Dade Behring).Abdominal ultrasonography (US) 
for hepatic scanning and evaluation of presence 
and/or severity of ascites and  Abdominal CT or 
MRI imaging were done for assurance of 
inclusion and exclusion criteria. 
 
2.2 Inclusion Criteria and Grouping 
 
1. Cirrhosis group: Clinically cirrhosis was 
defined by clinical development of 
esophageal varices, splenomegaly or small 
liver size with irregular liver surface on 
imaging studies. Cirrhotic patients were 
classified according to Child-Pugh scoring 
system, as shown in above Table 1, as 
Class A with total score of 5-6 indicating 
mild liver disease, Class B with total score 
of 7-9 indicating moderate liver disease 
and Class C with total score of 10-15 
indicating severe liver disease [20]. Only 
patients of Class A with total score of <7 
were enrolled in the study.  
2. Chronic hepatitis C (CHC) group: CHC 
infection was defined as hepatitis infection 
persisting for longer than 6 months with 
HCV antibody positive, increased serum 
ALT values and radiological assessment 
assured absence of any evidence of 
cancer.  
3. Hepatocellular carcinoma (HCC) group: 
HCC diagnosis depended on biopsy 
confirmed histological examination, or by 
either of CT or MRI imaging in patients 
with serum α-fetoprotein (AFP) level ≥400 
ng/ml [21].  
4. Control group: Fifteen volunteers collected 
from those attending hospital blood banks 
after passing pre-blood donation 
investigations were enrolled as controls for 
laboratory investigations after exclusion of 
criteria for patients' inclusion criteria for 
other groups. 
 
2.3 Exclusion Criteria 
 
Exclusion criteria included HBV co-infection, 
associated biliary diseases, possibility of extra-
hepatic diseases or malignancy, presence of 
other possible viral infections, current anti-viral 
therapy or advanced HCC. 
 
2.4 Investigations 
 
Fasting blood samples were withdrawn from all 
patients and controls and were divided into three 
parts: 
 
1- The 1
st
 part (3 ml) of the freshly drawn 
whole blood specimens was stored at 2-
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25°C for no more than 6 hours prior to 
centrifugation. Plasma were separated 
from whole blood within 6 hours of 
collection by centrifugation at 800-1600 x g 
for 20 minutes at room temperature. HCV 
RNA titers were quantitatively determined 
by real-time polymerase chain reaction 
(PCR) using COBAS TaqMan HCV 
quantitative test, version 2.0 (Roche 
Molecular Systems, Inc., Branchburg, NJ, 
USA) with a linear range from 43 to 
69,000,000 IU/ml according to 
manufacturer instructions [22]. Then, the 
log10 HCV RNA was calculated and 
considering the log10 value of 6 as cutoff 
log titer for HCV RNA levels corresponding 
to 10
6
 IU/ml, patients were categorized as 
high serum viral load if the log10 titer was > 
6 log titer of HCV RNA IU/ml and low 
serum viral load if the log10 H titer was ≤6 
log titer of HCV RNA IU/ml
 
[23]. 
2- The 2nd part of the freshly drawn blood 
sample was collected in plain tube and 
allowed to clot and centrifuged at 5000 rpm 
for 10 minutes and serum was collected 
and stored at -80°C till assayed for 
estimation of serum levels of AFP using 
the commercially available immunometric 
assay (Architect AFP assay, Abbott 
Laboratories, North Chicago, IL, USA) [24]. 
3- The 3
rd
 part  of the freshly drawn whole 
blood specimens were stored at 2-25°C for 
up to 24 hours followed by centrifugation to 
separate the serum, which was stored at -
80°C until used for molecular assay of 
miRs according to manufacturer's 
instructions. Briefly, RNA isolation and 
quantification of miR-215 and miR-141 is 
as following: 
 
- Total micro RNA was extracted from 
serum samples using RNeasy Protect 
Animal Blood kits (Qiagen kits) 
according to manufacture instructions. 
Two-step RT-PCR for miR-215 and 
miR-141 was performed using Qiagen 
miScript preAMP RT-PCR kit (Qiagen 
GmbH Hilden, Germany) for 
conversion of MiR to cDNA in a G-
storm thermocycler (UK). Then, 
amplification and quantification of miR-
215 and miR-141 was done by real 
time PCR in ABI 7900 (Applied 
Biosystem, USA) using SuperReal 
Premix Plus Quanti Tect. Kit, SYBR 
Green (Tiagen, Shanghai) according to 
manufacture's instructions and using 
the specific primers for each.  
- Real time cycler conditions were: 
 
- For miR-215:  Initial denaturation 
at 95°C for 15 min , followed by 45 
amplification cycles of 95°C for 5 
sec for denaturation, 58°C for 20 
sec for annealing and 72°C for 30 
sec for extension step. 
- For miR-141: Initial denaturation at  
95°C for 5 min , followed by 45 
amplification cycles of 95°C for 15 
sec for denaturation, 58°C for 30 
sec for annealing and 72°C for 30 
sec for extension step.  
- The reference gene 
(housekeeping gene) was U6 RNA 
to calculate the relative expression 
levels of MicroRNA-215 and micro 
RNA- 141.  
- Primer sequence as shown in    
above Table 2. 
- The cycle threshold (CT) which is 
the number of cycles required for 
the fluorescent signal to cross the 
threshold in real-time PCR serving 
as a tool for calculation of the 
starting template amount in each 
sample. Gene fold expression 
changes are calculated using the 
equation 2-∆∆ct using healthy 
controls as calibrator, where ∆∆Ct 
= [Ct (target, test)-Ct (reference, 
test)]-[Ct (target, calibrator)-Ct 
(reference, calibrator)] [25, 26,27]. 
 
2.5 Statistical Analysis  
 
Obtained data were presented as mean±SD, 
ranges, numbers and ratios. Results were 
analyzed using One-way ANOVA with post-hoc 
Tukey HSD Test and Chi-square test (X
2
 test). 
Possible relationships were investigated using 
Pearson linear regression. Sensitivity and 
positive predictive value (PPV=1-specificity) of 
estimated parameters as predictors were 
evaluated using the receiver operating 
characteristic (ROC) curve analysis judged by 
the area under the curve (AUC) compared 
versus the null hypothesis that AUC=0.05. 
Statistical analysis was conducted using the IBM 
SPSS Statistics, Version 23, 2015 (IBM Corp. 
Armonk, NY, USA) for Windows statistical 
package. P value <0.05 was considered 
statistically significant. 
 
3. RESULTS 
 
The study included 75 patients with hepatic 
diseases; 25 patients had liver cirrhosis 
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(Cirrhosis group), 25 patients with chronic 
hepatitis C (CHC group) and 25 patients with 
hepatocellular carcinoma (HCC group). The 
study also included 15 volunteers as control 
group. Patients of HCC group were significantly 
older and showed significantly: compromised 
liver function tests compared to controls and 
patients of other groups. Details of patients' 
enrolment data are shown in below Table 3. 
 
All patients showed significantly higher serum 
AFP levels compared to controls. However, 
serum AFP levels were significantly higher in 
HCC patients than cirrhosis patient and CHC 
patients with significantly higher levels estimated 
in CHC patients compared to cirrhosis patients 
(Fig. 1).  
 
Estimated relative expression levels of miR-215 
were significantly higher in CHC and HCC 
patients compared to both controls and cirrhosis 
patients with non-significantly higher serum 
levels estimated in HCC patients compared to 
CHC patients and in cirrhotic patients compared 
to controls (Fig. 2).  
 
On contrary, estimated relative expression levels 
of miR-141 were significantly lower in HCC and 
CHC patients compared to controls, while were 
non-significantly lower in cirrhotic compared to 
control. Mean serum miR-141 levels were 
significantly lower in HCC patients compared to 
cirrhotic patients, but were non-significantly lower 
compared to CHC patients with non-significant 
difference between cirrhotic and CHC patients 
(Table 4, Fig. 3). 
 
Estimation of HCV RNA viral load in CHC 
patients showed that 7 patients had log10 H titer 
of ≤6 and 18 patients had log10 H titer was >6. 
Serum viral load showed positive significant 
correlation (r=0.475, p=0.016) with serum 
expression level of miR-215 (Fig. 4), while 
showed positive non-significant correlation 
(r=0.24, p=0.318) with miR-141 in CHC patients 
(Fig. 5). 
 
Evaluation of the ability of estimated serum 
levels of MiR-215 and MiR-141 for differentiation 
between hepatic disease patients and controls, 
both markers showed that ability with AUC= 
0.872 and 0.250, respectively (Fig. 6). In 
comparison to the AUC for the null hypothesis 
(the reference AUC=0.5), AUC for MiR-215 more 
significantly higher (p=0.0006), but AUC for MiR-
141 was significantly lower (p=0.002). 
 
On the other hand, estimated serum levels of 
MiR-215 showed high ability to differentiate 
between patients with liver cirrhosis from CHC 
patients with AUC= 0.899 that was significant 
versus the reference AUC, while estimated 
serum expression levels of MiR-141 showed 
AUC=0.438 which is non-significantly lower than 
the reference AUC (Fig. 7). 
 
Evaluation of the ability of estimated serum 
levels of MiR-215 and MiR-141 for differentiation 
between HCC patients and patients with other 
hepatic disease showed that both markers are 
could identify HCC patients out of hepatic 
disease patients with AUC of 0.818 and 0.351, 
respectively (Fig. 8). In comparison to the 
reference AUC, AUC for MiR-215 more 
significantly higher (p=0.0007), but AUC for MiR-
141 was significantly (p=0.009) lower than the 
AUC for the null hypothesis (Table 5). 
 
Table 3. Demographic data and results of routine laboratory investigations of studied patients 
compared to controls 
 
Group variable  Control  Cirrhosis  CHC HCC 
Age (years) 48.9±7.6 51.2±9.1 52.2±11.6 59.6±10.4*†‡ 
Gender; M:F 11:4 17:8 15:10 18:7 
Liver 
function 
tests 
AST (IU/ml) 32.05±6.4 42.1±7.4 60.4±18.7*† 110±13.9*†‡ 
ALT (IU/ml) 28.3±3.9 50.8±7.9* 69.8±10.5*† 127.1±45.9*†‡ 
TB (mg/dl) 1.07±0.08 1.5±0.7* 1.73±0.4* 1.89±0.4*† 
Albumin (g/dl) 4.5±0.4 3.93±0.35* 4.02±0.33* 4±0.34* 
INR 1.02±0.13 1.13±0.15 1.3±0.29*† 1.38±0.37*† 
AFP (ng/ml) 1.96±0.6 24.1±14.5* 173±72.8*† 461.7±49.3*†‡ 
Data are presented as mean±SD; CHC: Chronic hepatitis C; HCC: Hepatocellular carcinoma; AST: Aspartate 
aminotransferase; ALT: Alanine aminotransferase; TB: Total bilirubin; AFP: α-fetoprotein; * indicates significance 
versus control levels; † indicates significance versus levels estimated in cirrhotic patients; ‡ indicates significance 
versus levels estimated in CHC patients; p<0.05 indicates significant difference;  
p>0.05 indicates non-significant difference 
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Fig. 1. Mean (+SD) serum AFP levels estimated in studied patients with varied liver diseases 
compared to controls 
 
 
 
Fig. 2. The relative expression level of the circulating microRNA-215 in studied patients with 
varied liver diseases compared to controls 
 
 
 
Fig. 3. The relative expression level of the circulating microRNA-141 in studied patients with 
varied liver diseases compared to controls
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Table 4. Mean serum AFP level and relative expression levels of MiR-215 and MiR-141 
estimated in studied groups 
 
Parameter  Control Cirrhosis CHC HCC 
AFP (ng/ml) Level 1.96±0.6 24.4±14.53 173±72.8 461.7±49.3 
P1  0.001 0.001 0.0001 
P2   =0.001 =0.001 
P3    =0.001 
Relative expression 
level of MiR-215 (ΔCT) 
Level 3.752±0.72 4.739±2.07 7.83±1.06 8.49±1.06 
P1  =0.072 =0.001 =0.001 
P2   =0.001 =0.001 
P3    =0.272 
Relative expression 
level of MiR-141 (ΔCT) 
 11.7±1.56 10.68±1.53 10.28±1.85 9.39±1.45 
P1  =0.223 =0.042 =0.001 
P2   =0.799 =0.028 
P3    =0.212 
Data are presented as mean±SD; AFP: α-fetoprotein; MiR: micro-RNA; CHC: Chronic hepatitis C; HCC: 
Hepatocellular carcinoma; P1 indicates significance versus control levels; P2 indicates significance versus levels 
estimated in cirrhotic patients; P3 indicates significance versus levels estimated in CHC patients; p<0.05 
indicates significant difference; p>0.05 indicates non-significant difference 
 
 
 
Fig. 4. Correlation between serum expression level of miR-215 and plasma HCV RNA viral load 
in patients with HCV 
 
 
 
Fig. 5. Correlation between serum expression level of miR-141 and plasma HCV RNA viral load 
in patients with HCV 
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Fig. 6. ROC curve analysis of ability of estimation of serum expression level of MiR-215 and 
MiR-141 for differentiation between normal controls and patients had liver disease 
 
 
 
Fig. 7. ROC curve analysis of ability of estimation of serum expression level of MiR-215 and 
MiR-141 for differentiation between cirrhotic and CHC patients 
 
Table 5. ROC curve analysis for applicability of estimation of serum expression levels of MiR-
215 and MiR-141 for differentiation between patients with varied hepatic diseases 
 
Purpose  Parameter AUC SE P value 95% CI 
Detection of hepatic disease MiR-215 0.872 0.037 0.0006 0.800-0.944 
MiR-141 0.250 0.066 =0.002 0.120-0.380 
Differentiation between CHC 
& cirrhosis  
MiR-215 0.899 0.044 <0.001 0.814-0.985 
MiR-141 0.438 0.083 NS 0.275-0.600 
Detection of HCC among 
liver disease patients 
MiR-215 0.818 0.049 0.0007 0.722-0.915 
MiR-141 0.315 0.062 0.009 0.194-0.436 
AUC: Area under curve; SE: Standard error; CI: Confidence interval; MiR: Micro-RNA: AUC>0.5 indicates high 
positive predictive value 
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Fig. 8. ROC curve analysis of ability of estimation of serum expression level of MiR-215 and 
MiR-141 for differentiation between HCC and other hepatic diseases 
 
4. DISCUSSION 
 
Noninvasive tools for the diagnosis of cancer has 
became a goal of many researchers. Liver 
diseases, especially cirrhosis and CHC which are 
the precursors of HCC are associated with serum 
expression of varied miR [17,18,19]. Considering 
that miR-141 functions as a tumor suppressor 
and inhibits the migration and invasion of HCC 
cells [20] and miR-215 was deregulated with 
microvascular invasion or growth advantage in 
HCC patients [28], so the current study targeted 
to evaluate the ability of estimation of serum 
expression levels of miR-141 and miR-215 to 
differentiate between liver cirrhosis, chronic 
hepatitis C (CHC) and hepatocellular carcinoma 
(HCC) patients. 
 
The obtained results fulfilled the aim of the study 
that estimation of serum expression levels of 
miR-141 and miR-215 can be used to 
differentiate between patients with liver diseases 
and free subjects on one side and HCC patients 
from patients with cirrhosis or CHC on the other 
side. These findings indicated the applicability of 
both miRs as serum markers for liver diseases, 
as non-invasive diagnostic modality for 
identification of HCC and supported that previous 
studies [12,29,30,31]
 
concerning the use of miRs 
as markers of liver diseases especially HCC. 
 
Estimated relative expression levels of miR-141 
were significantly lower in HCC patients 
compared to controls and cirrhotic patients and in 
CHC patients compared to controls, while in 
cirrhotic patients estimated levels were non-
significantly lower compared to the controls and 
non-significantly higher compared to CHC 
patients. These findings go in hand with the 
results of Liu et al. [32] findings using in situ 
hybridization analysis showing down-regulation 
of miR-141 in HCC tissues and cell lines and with 
Dhayat et al. [33] show circulating miR-200 
family members are significantly deregulated in 
patients with HCC and liver cirrhosis. These data 
indicate a tumor suppressive role for miR-141 in 
HCC patients and so its decreased expression 
levels indicate progressive or increased severity 
of HCC. In support of this assumption, Lou et al. 
[34] found MiR-141 over expression resulted in 
significantly reduced cell proliferation, invasion, 
and migration effects on HCC cells. 
 
In trial to explain the mechanism of tumor 
suppressive role for miR-141, Liu et al. [32] 
reported that miR-141 inhibits liver cancer cells 
by negatively regulating the T lymphoma 
invasion and metastasis 1 (Tiam1) gene, while 
Lin et al. [35] demonstrated that the repression of 
hepatocyte nuclear factor-3β by miR-141 
suppressed the proliferation and invasion and 
promoted the apoptosis of HepG2 cells. 
 
MiR-215, its estimated relative expression levels 
were significantly higher in CHC and HCC 
patients than controls and cirrhosis patients with 
non-significantly higher levels in HCC patients 
compared to CHC patients and in cirrhotic 
patients compared to controls. In line with these 
results Zhang et al. [36] detected significantly up-
regulated expression levels of miR-143 and miR-
215 in serum of patients with CHC and HCC. The 
currently obtained results spot light on a possible 
role of miR-215 in HCC tumorigensis and so its 
over-expression and high levels indicate 
increased disease severity. In line with this 
assumption, the current study detected positive 
significant correlation between serum viral load 
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and expression level of miR-215. To elucidate 
the mechanisms for miR-215 tumorigensis,      
Liu et al. [37] documented that HBV X (HBx) 
protein plays a vital role in the development of 
HCC through up-regulating miR-215. Wang et al. 
[38] demonstrated that the upregulation of 
miR-215 leads to the development of insensitivity 
to adriamycin and worsens the prognosis of HCC 
patients.  
 
The ROC curve analysis of the obtained results 
assured the ability of estimated serum levels of 
miR-141 and miR-215 for differentiation between 
hepatic disease patients and controls and 
between HCC patients and patients with cirrhosis 
or CHC, while miR-215 only could differentiate 
between patients with liver cirrhosis from CHC 
patients. Similarly, Zhang et al. [36] 
demonstrated that ROC analyses detected the 
potential application of miR-143 and miR-215 in 
the diagnosis of HCC.  
 
Moreover, serum expression levels of miRNA-
215 were correlated with CHC serum viral load 
and so could be used as a diagnostic and 
prognostic marker for CHC patients and may 
replace frequent estimation of hepatitis viral C 
load. This finding goes in hand with Kumar et al.
 
[39] detected significant positive correlation 
between micoRNA-122 level with and viral load.  
 
The obtained data point to the increased 
diagnostic yield of estimation of serum levels of 
miR-141 and miR-215 for differentiation between 
liver diseases and identification of HCC patients. 
Serum AFP also showed significant higher levels 
in all patient groups compared to controls with 
significantly higher level in HCC patients than 
patients of cirrhosis and CHC groups. In support 
of this assumption multiple previous studies 
recommended the use of more than one marker 
for prediction, screening or diagnosis of HCC 
[40,41,42,43]. Recently, in 2017, Zhang et al. [16] 
documented that efficacy of the combination of 3-
miRNA panel and AFP was powerful for HCC 
diagnosis, especially in early tumor screening. 
 
5. CONCLUSION 
 
Serum expression levels of MiR-215 and MiR- 
141 could identify hepatic disease patients with 
high PPV especially for MiR-215. MiR-215 can 
differentiate between cirrhosis and CHC patients 
and correlated with HCV load. Serum levels of 
both MiRs could assure diagnosis of HCC with 
high PPV. However, wider scale studies are 
mandatory for assurance of obtained results and 
identification of cutoff points for both MiRs to be 
applied as non-invasive diagnostic modalities. 
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